Search Results
Your search for it matches 16118 pages
Showing 10001 - 10050Expert Point of View: Lawrence Kaplan, MD
“This study is important because R-CHOP [rituximab and cyclophosphamide, doxorubicin, vincristine, prednisone] has been the standard of care for many years. CHOP, the chemotherapy backbone, has withstood challenges from more aggressive regimens in the past. The excellent clinical outcomes observed ...
Monica M. Bertagnolli, MD, Elected ASCO President for 2018–2019 Term
Monica M. Bertagnolli, MD, a long-time ASCO member and volunteer, has been elected to serve as the President of ASCO for the term beginning in June 2018. She will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2017. Additionally, three new members were elected to...
Weighing the Benefits and Risks of Medical Marijuana
Despite the fact that 28 states and the District of Columbia have enacted laws to permit the use of cannabis and cannabinoid-based drugs to treat medical conditions, including cancer and symptoms from its treatment, federal law prohibits physicians from prescribing marijuana to their patients,...
Dose-Adjusted EPOCH-R No Better Than R-CHOP in Diffuse Large B-Cell Lymphoma
Long-awaited results of the Cancer and Leukemia Group B (CALGB)/Alliance 50303 trial were a disappointment to many hematologists/oncologists at the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition. The study failed to show that dose-adjusted EPOCH-R (etoposide,...
Accelerating Progress in the Treatment of Glioblastoma Multiforme
W.K. Alfred Yung, MD, has wanted a career in medicine since he was a high-school student and has spent nearly 4 decades fulfilling that dream, specifically in the research and treatment of one of the deadliest cancers, malignant brain tumor, especially glioblastoma multiforme, the most common...
Expert Point of View: Brad S. Kahl, MD
Speaking about the GALLIUM study in the ASH News Daily, Brad S. Kahl, MD, of Washington University School of Medicine, St. Louis, commented, “It is a potentially practice-changing study that clearly shows an 8% absolute improvement in progression-free survival at 2 years for the patients getting...
Obinutuzumab Prolongs Disease-Free Survival vs Rituximab in Follicular Lymphoma
Induction and maintenance therapies with obinutuzumab (Gazyva) were superior to rituximab (Rituxan) induction and maintenance in patients with untreated follicular lymphoma, according to results of the phase III GALLIUM study presented at the Plenary Session during the 58th American Society of...
Study Identifies Factors in Clonal Evolution of Chemotherapy-Resistant Urothelial Carcinoma
In a study reported in Nature Genetics, Bishoy M. Faltas, MD, of Weill Cornell Medicine, and colleagues identified factors in the clonal evolution of chemotherapy-resistant urothelial carcinoma.1 As stated by the investigators: “Chemotherapy-resistant urothelial carcinoma has no uniformly curative...
Confirmation or Transformation? The Case of Palbociclib in Hormone Receptor–Positive Metastatic Breast Cancer
Women with hormone receptor–positive metastatic breast cancer are witnessing an unprecedented time of success in the battle against their disease. Just in the past 12 months, a number of prospective, randomized, phase III studies were reported, with positive results indicating the value of...
Expert Point of View: Sergio A. Giralt, MD
Sergio A. Giralt, MD, Chief of the Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center, New York, and the Melvin Berlin Family Chair in Multiple Myeloma, commented on the findings of the StaMINA trial for The ASCO Post. He said the results of the largest randomized U.S....
Single Autotransplant Not Enhanced by Additional Interventions in Multiple Myeloma
Additional interventions following upfront autologous stem cell transplant in multiple myeloma did not further improve progression-free or overall survival over transplant alone in a multicenter study presented as a late-breaking abstract at the 2016 American Society of Hematology (ASH) Annual...
Expert Point of View: Amir T. Fathi, MD
“In the past few years, there has been increased reporting of other, less traditional, response criteria in acute myeloid leukemia (AML), including morphologic leukemia-free state, partial response, and complete remission [or complete response] with incomplete recovery. There is some concern that...
Women in Oncology: Breaking Down Barriers and Looking to the Future
There has been no better time than the present for women in the field of oncology: Women at all stages of their careers are finding more opportunities and avenues to excel. At the time of the last ASCO workforce survey, women made up 28.4% of the oncologist workforce, and that proportion is rising...
Achieving Complete Response Is Key to Improving Survival in Older Patients With AML
The importance of achieving complete response after intensive therapy in older adults with acute myeloid leukemia (AML) was confirmed in a follow-up analysis of the E2906 North American Intergroup trial.1 Patients in complete response had superior survival in this landmark analysis. This finding...
Reducing Doses and Stopping Tyrosine Kinase Inhibitors Gain Favor in Chronic Myeloid Leukemia
Tyrosine kinase inhibitors, such as imatinib, nilotinib (Tasigna), and dasatinib (Sprycel), have revolutionized the treatment of chronic myeloid leukemia (CML). A substantial percentage of patients achieve deep and meaningful remissions on these agents. More recently, partly driven by patients’ and ...
A Gleason 6 Tumor: Is It Cancer, and Should It Be Treated?
The diagnosis and treatment of prostate cancer have long been a source of controversy among the oncology community, the political sector, and patient advocacy groups. Most notably, the decision to biopsy a man’s prostate gland rests largely on his prostate-specific antigen (PSA) test numbers, the...
As We Strive for a Cancer Cure, We Must Not Forget the Survivors
Although a cure for cancer remains elusive, there are many promising ideas to eradicate this disease, including the Cancer Moonshot Initiative and an ever-increasing body of cancer research that continually drives innovative treatments in an effort to improve survival and, ultimately, find a...
Expert Point of View: Michael Gnant, MD
Michael Gnant, MD, Professor of Surgery at the Medical University of Vienna in Austria and President of the Austrian Breast & Colorectal Cancer Study Group, was the invited discussant of the three studies of extended endocrine therapy. “The trials did not reach the necessary statistical levels ...
ESMO Asia 2016: Study Validates Set of Six Adaptable Prognosis Prediction Models for Patients With Cancer in Palliative Care Settings
A routine blood test may predict how long patients with cancer in palliative care will survive, researchers reported at the ESMO Asia 2016 Congress in Singapore. “Cancer patients in palliative care want honest and accurate prognostic information but this information needs to be shared...
ESMO Asia 2016: Depressed Patients May Be Less Responsive to Chemotherapy
A brain-boosting protein plays an important role in how well people respond to chemotherapy, researchers reported at the ESMO Asia 2016 Congress in Singapore. A study (Abstract 497O_PR) found that patients with cancer suffering from depression have decreased amounts of brain-derived neurotrophic...
ESMO Asia 2016: First Data Presented on Rare Sarcomas in Asian Patients
The first data on rare sarcomas in Asian patients were presented in three studies at the ESMO Asia 2016 Congress in Singapore. Just half of patients with advanced angiosarcoma received chemotherapy, although it improved overall survival. CIC-rearranged sarcomas were associated with a much worse...
Circulating Tumor DNA May Serve as a Prognostic Marker in Pancreatic Cancer
Translational research in pancreatic adenocarcinoma has been limited by the difficulty of obtaining sufficient quality and quantity tumor tissue from patients. A study by Pietrasz et al assessing the feasibility and prognostic value of circulating tumor DNA (ctDNA) in pancreatic adenocarcinoma has...
ESMO Asia 2016: Almost 20% of Swedish Breast Cancer Patients Fail to Complete Prescribed Endocrine Therapy
Around 20% of patients with breast cancer in Sweden do not complete endocrine therapy, according to research that will be reported at the ESMO Asia 2016 Congress (Abstract 62O_PR), to be held December 16–19 in Singapore.The study in over 5,500 women found that younger patients and those who...
Effectiveness of Electroacupuncture for Sleep Disturbances in Patients With Breast Cancer and Hot Flashes
Studies suggest that approximately 30% to 40% of women with breast cancer report persistent hot flashes. Nocturnal hot flashes are among the most problematic because they can contribute to poor sleep. A new study published by Garland et al in Menopause shows that electroacupuncture may be effective ...
Monica M. Bertagnolli, MD, Elected ASCO President for 2018–2019 Term
Monica M. Bertagnolli, MD, a long-time ASCO member and volunteer, has been elected to serve as the President of ASCO for the term beginning in June 2018. She will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2017. Additionally, three new members were elected to...
ASCO Clinical Practice Guideline on Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers
As reported in the Journal of Clinical Oncology by Saro H. Armenian, DO, MPH, of City of Hope, and colleagues, ASCO has released a clinical practice guideline on prevention and monitoring of cardiac dysfunction in survivors of adult cancers. Recommendations were developed by an expert panel using a ...
ESMO Asia 2016: Patients in India Wait an Average of 4 Months Before Seeking a Cancer Diagnosis
Patients in Chandigarh, India, waited an average of 4 months before seeking a cancer diagnosis, according to a recent study. Some patients waited less than a week before seeing a doctor—while others waited 3 years. The researchers will report their findings at the ESMO Asia 2016 Congress ...
SABCS 2016: IBM Watson for Oncology Platform Shows High Degree of Concordance With Physician Recommendations
The artificial-intelligence platform Watson for Oncology (WFO) achieved a high degree of concordance with the recommendations of a panel of oncologists in a double-blinded validation study, according to results presented at the 2016 San Antonio Breast Cancer Symposium, held December 6 to 10...
SABCS 2016: Aromatase Inhibitors Were Associated With Reduced Endothelial Function in Postmenopausal Breast Cancer Patients
Postmenopausal women with breast cancer who took aromatase inhibitors demonstrated endothelial dysfunction, a predictor of cardiovascular disease, according to study results presented at the 2016 San Antonio Breast Cancer Symposium, held December 6 to 10 (Abstract s5-07). Aromatase inhibitors are...
Pioneer in Cancer Immunology, Richmond T. Prehn, MD, Dies
Until 1957, the prevailing thought was that since cancers develop in normal patients, they are not recognized as foreign by the immune system. That changed when Richmond T. Prehn, MD, and his laboratory assistant, Joan Main, showed that tumors induced by chemical carcinogens in mice could...
Investigational Immunotherapy for Advanced Melanoma
The investigational immunotherapeutic IMC-20D7S was found to be well tolerated and somewhat active in patients with advanced melanoma, including one complete response, according to the results of a phase I/Ib trial reported by Danny N. Khalil, MD, PhD, and colleagues in Clinical Cancer Research....
SABCS 2016: Scalp-Cooling Device Safe and Effective in Reducing Chemotherapy-Induced Alopecia in Women With Breast Cancer
Although adjuvant chemotherapy decreases the risk of breast cancer recurrence, it is associated with distressing side effects, including hair loss. A prospective randomized trial evaluating the safety and efficacy of the Orbis Paxman Hair Loss Prevention System (OPHLPS), a scalp-cooling device that ...
Expect Questions About Cardiovascular Risk Factors Among Cancer Survivors
Reports of rare, but in some cases fatal, cardiac complications when the checkpoint inhibitors ipilimumab (Yervoy) and nivolumab (Opdivo) are used in combination should be taken seriously but should not scare patients away from potentially life-saving drugs, according to Javid J. Moslehi, MD. Dr....
Cardiac Complications in Patients Receiving Combination Checkpoint Inhibitors Are Rare but Can Be Fatal
Cardiovascular toxicities associated with cancer treatments are not new. What is new, and what has prompted recent articles in The New England Journal of Medicine,1,2 is the explosion of cancer therapies, which has dramatically changed the natural course of many cancers but can lead to cardiac,...
Overcoming the Physical, Emotional, and Financial Effects of Cancer
Although my diagnosis of stage IIIB melanoma 5 years ago came as a shock, in hindsight, it shouldn’t have been so surprising. I had noticed a small freckle-like lesion on my upper left thigh that had become itchy and occasionally bled, but it didn’t fit the ABCDE (Asymmetry, Border irregularity,...
Valerian
Scientific Names: Valeriana officinalis, Valeriana radix Common Names: Garden valerian, Indian valerian, Pacific valerian, garden heliotrope Overview A perennial flowering plant prevalent in Europe, Asia, and North America, valerian has a long medicinal history as a relaxant. Its potential as a...
SABCS 2016: BELLE-3 Trial of Buparlisib Plus Endocrine Therapy Meets Primary Endpoint of Progression-Free Survival in Breast Cancer Patients
The investigational PI3K inhibitor buparlisib, in combination with endocrine therapy, improved outcomes for patients with hormone receptor–positive advanced breast cancer that had progressed after treatment with everolimus (Afinitor) plus exemestane, according to data from the phase III...
Profound Answers to Simple Questions
A few years ago, I had the good fortune to join a research team that intended to create a device to help dying children express their wants and needs despite communication challenges. The brain tumor team at SickKids [also known as The Hospital for Sick Children] had cared for several children...
SABCS 2016: Radiation Therapy May Increase Complications in Breast Cancer Patients Receiving Implants
Radiotherapy increased complications and impaired patient-reported satisfaction with reconstructed breasts in breast cancer patients who received implant reconstruction, but not in those who received autologous reconstruction, according to data from a large, prospective, multicenter cohort study...
SABCS 2016: Adding Ibandronate to Hormone Therapy Did Not Improve Outcomes for Postmenopausal Breast Cancer Patients
Postmenopausal women with hormone receptor–positive early-stage breast cancer who received the bisphosphonate ibandronate (Boniva) in addition to adjuvant hormone therapy did not have improved disease-free survival outcomes, according to data from the phase III clinical trial TEAM IIB...
SABCS 2016: No Added Benefit With Aromatase Inhibitor as Part of Presurgical Therapy for Hormone Receptor–Positive, HER2-Positive Breast Cancer
Adding an aromatase inhibitor to presurgical treatment with docetaxel, carboplatin, trastuzumab (Herceptin), and pertuzumab (Perjeta) did not significantly increase or decrease the percentage of patients with hormone receptor–positive, HER2-positive breast cancer who had a pathologic...
Seven MD Anderson Faculty Elected Fellows of the American Association for the Advancement of Science
In recognition of wide-ranging contributions to the fields of cancer prevention; patient care; and basic, translational, and clinical research, seven faculty members from The University of Texas MD Anderson Cancer Center have been named Fellows of the American Association for the Advancement of...
Palliative Care Improves Quality of Life, Relieves Symptoms
People living with serious illness who receive palliative care have better quality of life and fewer symptoms than those who don’t receive palliative care, according to a new study by researchers at the University of Pittsburgh School of Medicine. Published by Dio Kavalieratos, PhD, Assistant...
Using Art to Humanize Medicine
Among the most widely attended sessions at the 2016 Palliative Care in Oncology Symposium in September was the keynote lecture, “Wit, Hex, Vin, Life, Death: Using Wit as a Teaching Tool,” given by Margaret Edson, author of the Pulitzer Prize–winning play Wit. Wit tells the story of an accomplished ...
Approval of Dinutuximab for High-Risk Neuroblastoma: Lessons Learned in Expediting the Development of Pediatric Cancer Drugs
On March 10, 2015, the U.S. Food and Drug Administration (FDA) granted regular approval to dinutuximab (formerly known as chimeric 14.18 antibody; Unituxin) for use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid...
Integrating AYA Oncology Care Into the Worlds of Pediatric and Adult Oncology Care to Improve Cancer Outcomes
GUEST EDITORAdolescent and Young Adult Oncology explores the unique physical, psychosocial, social, emotional, sexual, and financial challenges adolescents and young adults with cancer face. The column is guest edited by Brandon M. Hayes-Lattin, MD, FACP, Associate Professor of Medicine and...
Faculty Development in Oncology: Advancing the Field by Optimizing Opportunities for Educators to Learn and Grow
In 2015, Janet Riddle, MD, and her colleagues published an article1 outlining 12 key themes for delineating how fellowship programs in medical education should be developed (See “12 Tips for Developing Successful Fellowship Programs for Medical Educators,” below.) The ASCO Post talked with Dr....
Peer-Reviewed Indian Journal of Surgical Oncology Meets Challenges, Succeeds in Developing Country
Launching a new cancer journal is a risky and arduous endeavor, especially for a specialty publication in resource-challenged countries in the developing world. To succeed, a specialty journal must publish articles from established clinical researchers that quickly garner funding and captivate its...
The Leukemia & Lymphoma Society Invests $40.3 Million in New Research to Find Cures for Hematologic Malignancies
The Leukemia & Lymphoma Society (LLS) has announced it has committed $40.3 million in new research investments to advance the most promising blood cancer science at leading academic and medical centers around the world, including Dana-Farber Cancer Institute; Weill Cornell Medicine; Memorial...
Statement From the American Association for Cancer Research on the House Passage of the 21st Century Cures Act
From Nancy E. Davidson, MD, President of the AACR and Executive Director of the Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, and Margaret Foti, PhD, MD (hc), Chief Executive Officer of the AACR On behalf of the American Association for Cancer Research (AACR),...
